Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the appointment of Carri Duncan, PhD, as Vice President Corporate Development & Communications, effective as of October 1st, 2018.
Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the appointment of Carri Duncan, PhD, as Vice President Corporate Development & Communications, effective as of October 1st, 2018. This is yet another strategic hire to prepare Celyad for its next level of success.
Carri brings broad expertise in Life Science, most recently as VP Investor Relations at Bayer. Prior to that, she worked at Egon Zehnder as a Management Consultant in the Life Science and Finance practice groups. In previous years, Carri worked as an equities analyst including on the Buy-side at Credit Suisse, where she has pioneered coverage of European Biotech equities.
For over a decade, Carri worked as a molecular and cell biologist in academia and with Novartis and Eli Lilly in areas of developmental biology and cancer research, respectively. She earned a PhD in Neuroscience from the ETH-Zurich.
Dr. Christian Homsy, CEO of Celyad: “We are pleased to welcome Carri in our senior leadership team. Carri’s rich experience and sharp analytical skills makes her a perfect fit to lead our corporate development and steer our business strategy. She will be key in designing Celyad’s overall development and further improving our operational excellence.”
Dr. Carri Duncan, VP Corporate Development and Communications: “I’m excited to join Celyad’s talented team in its ambition to transform Oncology. As one of the most promising CAR-T companies at this stage of development and with its unique IP position, I see a great opportunity to use my portfolio of experience, expertise and networks to the further advancement of Celyad.”
Dr. Duncan will be based in Mont-Saint-Guibert, Belgium and will report to Dr. Christian Homsy, Chief Executive Officer.
